English
简体中文
Total: £ 56.28
Published Date: 2026-02-06 | Pages: 135 | Tables: 139 | Pharma & Healthcare
The global Gout Medications market was valued at US$ 3874 million in 2025 and is anticipated to reach US$ 6391 million by 2032, at a CAGR of 7.5% from 2026 to 2032.
Gout medications comprise agents for prevention and treatment of gout and hyperuricemia, including anti-inflammatory analgesics for acute attacks, xanthine oxidase inhibitors and uricosurics for long-term uric acid control, and emerging targeted small molecules and biologics. The therapeutic aim extends beyond acute pain relief to sustained control of serum urate to prevent joint destruction, tophi formation, and renal complications. With expanding populations affected by metabolic disorders and the widespread adoption of chronic disease management, clinical practice is shifting from episodic attack treatment toward continuous metabolic control, increasing demand for combination therapies, personalized regimens, and adherence-supporting solutions. Pharmaceutical innovations in novel molecular targets, extended-release formulations, and integration with digital therapeutics are set to enhance both market value and patient outcomes, creating new requirements across upstream raw materials, manufacturing, and distribution networks.The average gross profit margin in this industry is 60%。
Structural growth opportunities continue to expand the gout medications market globally. Corporate annual reports and brokerage analyses consistently highlight that the growing chronic metabolic population, increased patient awareness of long-term management, and broader reimbursement coverage together amplify sustained demand for uric acid control and complication prevention therapies. R&D investment is shifting toward precision targets and long-acting delivery, enabling differentiated medicines with adherence advantages to rapidly capture market positions. The commercialization of digital health and chronic care services also offers pharmaceutical firms embedded therapy models and monetizable value-added services, attracting capital and marketing focus.
Despite clear opportunities, the sector faces pressures from post-patent generic incursions, intensifying price competition, and tightened regulatory and compliance requirements. Corporate reports flag risks related to concentrated raw material supply chains and rising environmental compliance costs; broker research warns that safety controversies or regulatory constraints can rapidly alter a drug’s market outlook. Moreover, the chronic nature of gout treatment and suboptimal patient adherence mean many potential market opportunities face conversion barriers into sustained prescriptions and long-term medication use, requiring firms to invest more in product design, patient support, and channel capabilities to secure commercial returns.
Clinical and end-market demand is shifting from acute attack treatment toward prevention and long-term management, with hospitals, specialty clinics, and retail channels forming a multi-channel distribution ecosystem. Annual reports and government health policies show that the expansion of community chronic care and online medical services is reshaping prescribing pathways and patient purchasing behavior, prompting pharmaceutical companies to pivot from single-course promotion to long-term adherence support and integrated treatment solutions. Rising demand for customized combination therapies, extended-release formulations, and follow-up services gives an edge to firms with full-stack channel and service capabilities.
The upstream segment for gout medications centers on high-purity organic intermediates, key small-molecule APIs, and formulation excipients, with supply chains reliant on large-scale synthesis suppliers. Annual reports indicate that upstream capacity deployment and GMP compliance are critical to ensuring product quality and delivery; broker and regulatory communications emphasize the importance of environmental compliance and supply diversification. As novel molecules and complex formulations increase, upstream firms must continue investing in green chemistry, process scale-up, and stringent quality controls to meet downstream commercial expectations for reliable, traceable, and compliant supply.
This report delivers a comprehensive overview of the global Gout Medications market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Gout Medications. The Gout Medications market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Gout Medications market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Gout Medications manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Takeda Pharmaceuticals
Hermann Germany
Aspen
Teijin Pharma
Horizon Pharmaceuticals
Novartis
Wanbang Biopharmaceuticals
Hengrui Medicine
London Reddy
East Sunshine Pharmaceuticals
Kunming Pharmaceuticals
Heilongjiang Auridanide
Jingde Pharmaceutical Factory
Tianjie Biopharmaceuticals
Shanghai Pharmaceuticals
Chengdu Taihe Health
Segment by Type
Febuxostat
Benzbromarone
NSAIDs
Colchicine
Glucocorticoids
Allopurinol
Other
Segment by Application
Primary Gout
Secondary Gout
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Gout Medications companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gout Medications Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Febuxostat
1.2.3 Benzbromarone
1.2.4 NSAIDs
1.2.5 Colchicine
1.2.6 Glucocorticoids
1.2.7 Allopurinol
1.2.8 Other
1.3 Market by Application
1.3.1 Global Gout Medications Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Primary Gout
1.3.3 Secondary Gout
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gout Medications Market Perspective (2021–2032)
2.2 Global Gout Medications Growth Trends by Region
2.2.1 Global Gout Medications Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Gout Medications Historic Market Size by Region (2021–2026)
2.2.3 Gout Medications Forecasted Market Size by Region (2027–2032)
2.3 Gout Medications Market Dynamics
2.3.1 Gout Medications Industry Trends
2.3.2 Gout Medications Market Drivers
2.3.3 Gout Medications Market Challenges
2.3.4 Gout Medications Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gout Medications Players by Revenue
3.1.1 Global Top Gout Medications Players by Revenue (2021–2026)
3.1.2 Global Gout Medications Revenue Market Share by Players (2021–2026)
3.2 Global Top Gout Medications Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Gout Medications Revenue
3.4 Global Gout Medications Market Concentration Ratio
3.4.1 Global Gout Medications Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gout Medications Revenue in 2025
3.5 Global Key Players of Gout Medications Head Offices and Areas Served
3.6 Global Key Players of Gout Medications, Products and Applications
3.7 Global Key Players of Gout Medications, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Gout Medications Breakdown Data by Type
4.1 Global Gout Medications Historic Market Size by Type (2021–2026)
4.2 Global Gout Medications Forecasted Market Size by Type (2027–2032)
5 Gout Medications Breakdown Data by Application
5.1 Global Gout Medications Historic Market Size by Application (2021–2026)
5.2 Global Gout Medications Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Gout Medications Market Size (2021–2032)
6.2 North America Gout Medications Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Gout Medications Market Size by Country (2021–2026)
6.4 North America Gout Medications Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gout Medications Market Size (2021–2032)
7.2 Europe Gout Medications Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Gout Medications Market Size by Country (2021–2026)
7.4 Europe Gout Medications Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Gout Medications Market Size (2021–2032)
8.2 Asia-Pacific Gout Medications Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Gout Medications Market Size by Region (2021–2026)
8.4 Asia-Pacific Gout Medications Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Gout Medications Market Size (2021–2032)
9.2 Latin America Gout Medications Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Gout Medications Market Size by Country (2021–2026)
9.4 Latin America Gout Medications Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gout Medications Market Size (2021–2032)
10.2 Middle East & Africa Gout Medications Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Gout Medications Market Size by Country (2021–2026)
10.4 Middle East & Africa Gout Medications Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Takeda Pharmaceuticals
11.1.1 Takeda Pharmaceuticals Company Details
11.1.2 Takeda Pharmaceuticals Business Overview
11.1.3 Takeda Pharmaceuticals Gout Medications Introduction
11.1.4 Takeda Pharmaceuticals Revenue in Gout Medications Business (2021–2026)
11.1.5 Takeda Pharmaceuticals Recent Development
11.2 Hermann Germany
11.2.1 Hermann Germany Company Details
11.2.2 Hermann Germany Business Overview
11.2.3 Hermann Germany Gout Medications Introduction
11.2.4 Hermann Germany Revenue in Gout Medications Business (2021–2026)
11.2.5 Hermann Germany Recent Development
11.3 Aspen
11.3.1 Aspen Company Details
11.3.2 Aspen Business Overview
11.3.3 Aspen Gout Medications Introduction
11.3.4 Aspen Revenue in Gout Medications Business (2021–2026)
11.3.5 Aspen Recent Development
11.4 Teijin Pharma
11.4.1 Teijin Pharma Company Details
11.4.2 Teijin Pharma Business Overview
11.4.3 Teijin Pharma Gout Medications Introduction
11.4.4 Teijin Pharma Revenue in Gout Medications Business (2021–2026)
11.4.5 Teijin Pharma Recent Development
11.5 Horizon Pharmaceuticals
11.5.1 Horizon Pharmaceuticals Company Details
11.5.2 Horizon Pharmaceuticals Business Overview
11.5.3 Horizon Pharmaceuticals Gout Medications Introduction
11.5.4 Horizon Pharmaceuticals Revenue in Gout Medications Business (2021–2026)
11.5.5 Horizon Pharmaceuticals Recent Development
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Gout Medications Introduction
11.6.4 Novartis Revenue in Gout Medications Business (2021–2026)
11.6.5 Novartis Recent Development
11.7 Wanbang Biopharmaceuticals
11.7.1 Wanbang Biopharmaceuticals Company Details
11.7.2 Wanbang Biopharmaceuticals Business Overview
11.7.3 Wanbang Biopharmaceuticals Gout Medications Introduction
11.7.4 Wanbang Biopharmaceuticals Revenue in Gout Medications Business (2021–2026)
11.7.5 Wanbang Biopharmaceuticals Recent Development
11.8 Hengrui Medicine
11.8.1 Hengrui Medicine Company Details
11.8.2 Hengrui Medicine Business Overview
11.8.3 Hengrui Medicine Gout Medications Introduction
11.8.4 Hengrui Medicine Revenue in Gout Medications Business (2021–2026)
11.8.5 Hengrui Medicine Recent Development
11.9 London Reddy
11.9.1 London Reddy Company Details
11.9.2 London Reddy Business Overview
11.9.3 London Reddy Gout Medications Introduction
11.9.4 London Reddy Revenue in Gout Medications Business (2021–2026)
11.9.5 London Reddy Recent Development
11.10 East Sunshine Pharmaceuticals
11.10.1 East Sunshine Pharmaceuticals Company Details
11.10.2 East Sunshine Pharmaceuticals Business Overview
11.10.3 East Sunshine Pharmaceuticals Gout Medications Introduction
11.10.4 East Sunshine Pharmaceuticals Revenue in Gout Medications Business (2021–2026)
11.10.5 East Sunshine Pharmaceuticals Recent Development
11.11 Kunming Pharmaceuticals
11.11.1 Kunming Pharmaceuticals Company Details
11.11.2 Kunming Pharmaceuticals Business Overview
11.11.3 Kunming Pharmaceuticals Gout Medications Introduction
11.11.4 Kunming Pharmaceuticals Revenue in Gout Medications Business (2021–2026)
11.11.5 Kunming Pharmaceuticals Recent Development
11.12 Heilongjiang Auridanide
11.12.1 Heilongjiang Auridanide Company Details
11.12.2 Heilongjiang Auridanide Business Overview
11.12.3 Heilongjiang Auridanide Gout Medications Introduction
11.12.4 Heilongjiang Auridanide Revenue in Gout Medications Business (2021–2026)
11.12.5 Heilongjiang Auridanide Recent Development
11.13 Jingde Pharmaceutical Factory
11.13.1 Jingde Pharmaceutical Factory Company Details
11.13.2 Jingde Pharmaceutical Factory Business Overview
11.13.3 Jingde Pharmaceutical Factory Gout Medications Introduction
11.13.4 Jingde Pharmaceutical Factory Revenue in Gout Medications Business (2021–2026)
11.13.5 Jingde Pharmaceutical Factory Recent Development
11.14 Tianjie Biopharmaceuticals
11.14.1 Tianjie Biopharmaceuticals Company Details
11.14.2 Tianjie Biopharmaceuticals Business Overview
11.14.3 Tianjie Biopharmaceuticals Gout Medications Introduction
11.14.4 Tianjie Biopharmaceuticals Revenue in Gout Medications Business (2021–2026)
11.14.5 Tianjie Biopharmaceuticals Recent Development
11.15 Shanghai Pharmaceuticals
11.15.1 Shanghai Pharmaceuticals Company Details
11.15.2 Shanghai Pharmaceuticals Business Overview
11.15.3 Shanghai Pharmaceuticals Gout Medications Introduction
11.15.4 Shanghai Pharmaceuticals Revenue in Gout Medications Business (2021–2026)
11.15.5 Shanghai Pharmaceuticals Recent Development
11.16 Chengdu Taihe Health
11.16.1 Chengdu Taihe Health Company Details
11.16.2 Chengdu Taihe Health Business Overview
11.16.3 Chengdu Taihe Health Gout Medications Introduction
11.16.4 Chengdu Taihe Health Revenue in Gout Medications Business (2021–2026)
11.16.5 Chengdu Taihe Health Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Gout Medications Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Febuxostat
Table 3. Key Players of Benzbromarone
Table 4. Key Players of NSAIDs
Table 5. Key Players of Colchicine
Table 6. Key Players of Glucocorticoids
Table 7. Key Players of Allopurinol
Table 8. Key Players of Other
Table 9. Global Gout Medications Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 10. Global Gout Medications Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 11. Global Gout Medications Market Size by Region (US$ Million), 2021–2026
Table 12. Global Gout Medications Market Share by Region (2021–2026)
Table 13. Global Gout Medications Forecasted Market Size by Region (US$ Million), 2027–2032
Table 14. Global Gout Medications Market Share by Region (2027–2032)
Table 15. Gout Medications Market Trends
Table 16. Gout Medications Market Drivers
Table 17. Gout Medications Market Challenges
Table 18. Gout Medications Market Restraints
Table 19. Global Gout Medications Revenue by Players (US$ Million), 2021–2026
Table 20. Global Gout Medications Market Share by Players (2021–2026)
Table 21. Global Top Gout Medications Players by Tier (Tier 1, Tier 2, and Tier 3), based on Gout Medications Revenue, 2025
Table 22. Ranking of Global Top Gout Medications Companies by Revenue (US$ Million) in 2025
Table 23. Global 5 Largest Players Market Share by Gout Medications Revenue (CR5 and HHI), 2021–2026
Table 24. Global Key Players of Gout Medications, Headquarters and Area Served
Table 25. Global Key Players of Gout Medications, Products and Applications
Table 26. Global Key Players of Gout Medications, Date of General Availability (GA)
Table 27. Mergers and Acquisitions, Expansion Plans
Table 28. Global Gout Medications Market Size by Type (US$ Million), 2021–2026
Table 29. Global Gout Medications Revenue Market Share by Type (2021–2026)
Table 30. Global Gout Medications Forecasted Market Size by Type (US$ Million), 2027–2032
Table 31. Global Gout Medications Revenue Market Share by Type (2027–2032)
Table 32. Global Gout Medications Market Size by Application (US$ Million), 2021–2026
Table 33. Global Gout Medications Revenue Market Share by Application (2021–2026)
Table 34. Global Gout Medications Forecasted Market Size by Application (US$ Million), 2027–2032
Table 35. Global Gout Medications Revenue Market Share by Application (2027–2032)
Table 36. North America Gout Medications Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 37. North America Gout Medications Market Size by Country (US$ Million), 2021–2026
Table 38. North America Gout Medications Market Size by Country (US$ Million), 2027–2032
Table 39. Europe Gout Medications Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 40. Europe Gout Medications Market Size by Country (US$ Million), 2021–2026
Table 41. Europe Gout Medications Market Size by Country (US$ Million), 2027–2032
Table 42. Asia-Pacific Gout Medications Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 43. Asia-Pacific Gout Medications Market Size by Region (US$ Million), 2021–2026
Table 44. Asia-Pacific Gout Medications Market Size by Region (US$ Million), 2027–2032
Table 45. Latin America Gout Medications Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 46. Latin America Gout Medications Market Size by Country (US$ Million), 2021–2026
Table 47. Latin America Gout Medications Market Size by Country (US$ Million), 2027–2032
Table 48. Middle East & Africa Gout Medications Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 49. Middle East & Africa Gout Medications Market Size by Country (US$ Million), 2021–2026
Table 50. Middle East & Africa Gout Medications Market Size by Country (US$ Million), 2027–2032
Table 51. Takeda Pharmaceuticals Company Details
Table 52. Takeda Pharmaceuticals Business Overview
Table 53. Takeda Pharmaceuticals Gout Medications Product
Table 54. Takeda Pharmaceuticals Revenue in Gout Medications Business (US$ Million), 2021–2026
Table 55. Takeda Pharmaceuticals Recent Development
Table 56. Hermann Germany Company Details
Table 57. Hermann Germany Business Overview
Table 58. Hermann Germany Gout Medications Product
Table 59. Hermann Germany Revenue in Gout Medications Business (US$ Million), 2021–2026
Table 60. Hermann Germany Recent Development
Table 61. Aspen Company Details
Table 62. Aspen Business Overview
Table 63. Aspen Gout Medications Product
Table 64. Aspen Revenue in Gout Medications Business (US$ Million), 2021–2026
Table 65. Aspen Recent Development
Table 66. Teijin Pharma Company Details
Table 67. Teijin Pharma Business Overview
Table 68. Teijin Pharma Gout Medications Product
Table 69. Teijin Pharma Revenue in Gout Medications Business (US$ Million), 2021–2026
Table 70. Teijin Pharma Recent Development
Table 71. Horizon Pharmaceuticals Company Details
Table 72. Horizon Pharmaceuticals Business Overview
Table 73. Horizon Pharmaceuticals Gout Medications Product
Table 74. Horizon Pharmaceuticals Revenue in Gout Medications Business (US$ Million), 2021–2026
Table 75. Horizon Pharmaceuticals Recent Development
Table 76. Novartis Company Details
Table 77. Novartis Business Overview
Table 78. Novartis Gout Medications Product
Table 79. Novartis Revenue in Gout Medications Business (US$ Million), 2021–2026
Table 80. Novartis Recent Development
Table 81. Wanbang Biopharmaceuticals Company Details
Table 82. Wanbang Biopharmaceuticals Business Overview
Table 83. Wanbang Biopharmaceuticals Gout Medications Product
Table 84. Wanbang Biopharmaceuticals Revenue in Gout Medications Business (US$ Million), 2021–2026
Table 85. Wanbang Biopharmaceuticals Recent Development
Table 86. Hengrui Medicine Company Details
Table 87. Hengrui Medicine Business Overview
Table 88. Hengrui Medicine Gout Medications Product
Table 89. Hengrui Medicine Revenue in Gout Medications Business (US$ Million), 2021–2026
Table 90. Hengrui Medicine Recent Development
Table 91. London Reddy Company Details
Table 92. London Reddy Business Overview
Table 93. London Reddy Gout Medications Product
Table 94. London Reddy Revenue in Gout Medications Business (US$ Million), 2021–2026
Table 95. London Reddy Recent Development
Table 96. East Sunshine Pharmaceuticals Company Details
Table 97. East Sunshine Pharmaceuticals Business Overview
Table 98. East Sunshine Pharmaceuticals Gout Medications Product
Table 99. East Sunshine Pharmaceuticals Revenue in Gout Medications Business (US$ Million), 2021–2026
Table 100. East Sunshine Pharmaceuticals Recent Development
Table 101. Kunming Pharmaceuticals Company Details
Table 102. Kunming Pharmaceuticals Business Overview
Table 103. Kunming Pharmaceuticals Gout Medications Product
Table 104. Kunming Pharmaceuticals Revenue in Gout Medications Business (US$ Million), 2021–2026
Table 105. Kunming Pharmaceuticals Recent Development
Table 106. Heilongjiang Auridanide Company Details
Table 107. Heilongjiang Auridanide Business Overview
Table 108. Heilongjiang Auridanide Gout Medications Product
Table 109. Heilongjiang Auridanide Revenue in Gout Medications Business (US$ Million), 2021–2026
Table 110. Heilongjiang Auridanide Recent Development
Table 111. Jingde Pharmaceutical Factory Company Details
Table 112. Jingde Pharmaceutical Factory Business Overview
Table 113. Jingde Pharmaceutical Factory Gout Medications Product
Table 114. Jingde Pharmaceutical Factory Revenue in Gout Medications Business (US$ Million), 2021–2026
Table 115. Jingde Pharmaceutical Factory Recent Development
Table 116. Tianjie Biopharmaceuticals Company Details
Table 117. Tianjie Biopharmaceuticals Business Overview
Table 118. Tianjie Biopharmaceuticals Gout Medications Product
Table 119. Tianjie Biopharmaceuticals Revenue in Gout Medications Business (US$ Million), 2021–2026
Table 120. Tianjie Biopharmaceuticals Recent Development
Table 121. Shanghai Pharmaceuticals Company Details
Table 122. Shanghai Pharmaceuticals Business Overview
Table 123. Shanghai Pharmaceuticals Gout Medications Product
Table 124. Shanghai Pharmaceuticals Revenue in Gout Medications Business (US$ Million), 2021–2026
Table 125. Shanghai Pharmaceuticals Recent Development
Table 126. Chengdu Taihe Health Company Details
Table 127. Chengdu Taihe Health Business Overview
Table 128. Chengdu Taihe Health Gout Medications Product
Table 129. Chengdu Taihe Health Revenue in Gout Medications Business (US$ Million), 2021–2026
Table 130. Chengdu Taihe Health Recent Development
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
Table 134. Authors List of This Report
List of Figures
Figure 1. Gout Medications Picture
Figure 2. Global Gout Medications Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Gout Medications Market Share by Type: 2025 vs 2032
Figure 4. Febuxostat Features
Figure 5. Benzbromarone Features
Figure 6. NSAIDs Features
Figure 7. Colchicine Features
Figure 8. Glucocorticoids Features
Figure 9. Allopurinol Features
Figure 10. Other Features
Figure 11. Global Gout Medications Market Size by Application (US$ Million), 2021–2032
Figure 12. Global Gout Medications Market Share by Application: 2025 vs 2032
Figure 13. Primary Gout Case Studies
Figure 14. Secondary Gout Case Studies
Figure 15. Gout Medications Report Years Considered
Figure 16. Global Gout Medications Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 17. Global Gout Medications Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 18. Global Gout Medications Market Share by Region: 2025 vs 2032
Figure 19. Global Gout Medications Market Share by Players in 2025
Figure 20. Global Gout Medications Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 21. The Top 10 and 5 Players Market Share by Gout Medications Revenue in 2025
Figure 22. North America Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. North America Gout Medications Market Share by Country (2021–2032)
Figure 24. United States Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Canada Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. Europe Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. Europe Gout Medications Market Share by Country (2021–2032)
Figure 28. Germany Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. France Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. U.K. Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Italy Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Russia Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Ireland Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Asia-Pacific Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Asia-Pacific Gout Medications Market Share by Region (2021–2032)
Figure 36. China Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Japan Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. South Korea Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Southeast Asia Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. India Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Australia & New Zealand Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Latin America Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Latin America Gout Medications Market Share by Country (2021–2032)
Figure 44. Mexico Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Brazil Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Middle East & Africa Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Middle East & Africa Gout Medications Market Share by Country (2021–2032)
Figure 48. Israel Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Saudi Arabia Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. UAE Gout Medications Market Size YoY Growth (US$ Million), 2021–2032
Figure 51. Takeda Pharmaceuticals Revenue Growth Rate in Gout Medications Business (2021–2026)
Figure 52. Hermann Germany Revenue Growth Rate in Gout Medications Business (2021–2026)
Figure 53. Aspen Revenue Growth Rate in Gout Medications Business (2021–2026)
Figure 54. Teijin Pharma Revenue Growth Rate in Gout Medications Business (2021–2026)
Figure 55. Horizon Pharmaceuticals Revenue Growth Rate in Gout Medications Business (2021–2026)
Figure 56. Novartis Revenue Growth Rate in Gout Medications Business (2021–2026)
Figure 57. Wanbang Biopharmaceuticals Revenue Growth Rate in Gout Medications Business (2021–2026)
Figure 58. Hengrui Medicine Revenue Growth Rate in Gout Medications Business (2021–2026)
Figure 59. London Reddy Revenue Growth Rate in Gout Medications Business (2021–2026)
Figure 60. East Sunshine Pharmaceuticals Revenue Growth Rate in Gout Medications Business (2021–2026)
Figure 61. Kunming Pharmaceuticals Revenue Growth Rate in Gout Medications Business (2021–2026)
Figure 62. Heilongjiang Auridanide Revenue Growth Rate in Gout Medications Business (2021–2026)
Figure 63. Jingde Pharmaceutical Factory Revenue Growth Rate in Gout Medications Business (2021–2026)
Figure 64. Tianjie Biopharmaceuticals Revenue Growth Rate in Gout Medications Business (2021–2026)
Figure 65. Shanghai Pharmaceuticals Revenue Growth Rate in Gout Medications Business (2021–2026)
Figure 66. Chengdu Taihe Health Revenue Growth Rate in Gout Medications Business (2021–2026)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
